From: Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas
GEO accession | Group | Samples | Probes | Platform |
---|---|---|---|---|
GSE4732_p1 | Dave et al. [30] | 54 BL, 249 DLBCL | 2745 | Custom Affymetrix Lympho-Chip |
GSE4732_p2 | Dave et al. [30] | 33 BL, 66 DLBCL | 54,675 | Affymetrix HG-U133 plus2.0 |
GSE4475 | Hummel et al. [31] | 44 mBL, 48 intermediate, 129 non-mBL | 22,283 | Affymetrix HG-U133A |
GSE10172 | Klapper et al. [56] | 13 mBL, 9 intermediate, 14 non-mBL | 22,283 | Affymetrix HG-U133A |
GSE26673 | Piccaluga et al. [57] | 13 eBL, 2 HIV-BL | 54,675 | Affymetrix HG-U133 plus2.0 |
GSE17189 | Deffenbacher et al. [58] | 4 HIV-BL, 13 HIV-DLBCL | 54,675 | Affymetrix HG-U133 plus2.0 |
 | HMDS | 41 BL, 206 DLBCL clinically diagnosed | 24,526 | Illumina WG-DASL Version_3 |
 | HMDS | 70 BL, 169 DLBCL clinically diagnosed | 29,377 | Illumina WG-DASL Version_4 |